Breast cancer is the second-largest cause of cancer deaths globally. Breast cancer treatment is seen as a major focus area for governments in several developed and developing countries due to growing awareness about the disease. Drugs used in the treatment of breast cancer range from regular regimens to biologicals. The market is witnessing strong growth driven by increasing awareness among the population and premium priced therapies being introduced by pharmaceutical manufacturers. Moreover, drugs for breast cancer have seen accelerated approvals, thereby providing impetus for breast cancer research and shifting the equilibrium toward research of new effective pathways for intervention of breast cancer.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/1425
The major classes of drugs for breast cancer are HER2 inhibitors, anti-metabolites, aromatase inhibitors, mitotic inhibitors, and hormone receptors antagonists. The HER2 inhibitors segment dominated the market in 2014. High cost and accurate diagnosis are attributed to the dominance of the segment of the breast cancer therapeutics market. On the other hand, recently launched molecule, Ibrance, is projected to be the fastest growing drug in the breast cancer therapeutics market.
Inquiry on this report @ http://www.mrrse.com/enquiry/1425
Geographically, North America dominated the global breast cancer therapeutics market in 2014 due to favorable insurance system that entitles high price of products. Moreover, entry of major pharmaceutical companies in the U.S. and high prevalence of breast cancer are the other factors that drive the market in North America. The market in Asia Pacific is anticipated to witness the fastest growth due to rising incidence, growing awareness about breast cancer, and standpoint taken by major governments of APAC countries to alleviate breast cancer as national health program.
Read Complete Report with TOC @ http://www.mrrse.com/breast-cancer-therapeutics-pipeline-analysis-market
The breast cancer therapeutics market exhibits strong demand for combination therapies to increase the overall efficiency of the treatment. Major players operating in the breast cancer therapeutic market are Genentech, Inc. (a Roche company), Eisai Co. Ltd., Eli Lilly and Company, Pfizer, Inc., Novartis AG, AstraZeneca plc, and Sanofi S.A.
90 State Street,
Albany NY – 12207